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aince it was first reported 50 years ago, the long QT
yndrome (LQTS) is now recognized as a genetic disease
aused by mutations of ion channel genes encoding a cardiac
hannel essential for the control of ventricular repolarization
1). The LQTS is not only the most common and exten-
ively researched genetic cardiac arrhythmia (2,3), it has also
ttracted premier scientists and scholars in single-cell elec-
rophysiology and molecular genetics. In turn, they have
roduced seminal discoveries that shaped our understanding
f the syndrome. The mutated genes in LQTS patients
ause delayed repolarization and, in turn, prolong the QT
nterval on the surface electrocardiogram; these abnormali-
ies are associated with torsade de pointes and/or ventricular
brillation, resulting in the clinical manifestation of syncope
nd/or sudden death (2,3).
See page 2052
Currently, there are hundreds of mutations in 10 genes
inked to LQTS, which have been genetically subtyped into
QT1 through LQT8 (3). However, 95% of these cases
nvolve LQT1 through LQT3. These common forms of
QTS have different genes coding various ion channel sub-
nits, making an impact on the diagnosis and management of
QTS patients. The most common form is LQT1, which is
aused by the loss-of-function mutation in KCNQ1, which
ncodes IKs, an adrenergic-sensitive potassium current of the
ardiac myocytes. Thus, LQT1 patients usually have symp-
oms after emotional or physical stress, notably diving or
wimming. Not surprisingly, LQT1 patients respond very well
o -blockade treatment, and exercise may aggravate QT
rolongation. The LQT2 subtype is caused by loss-of-function
utations in KCNH2 (hERG), which encodes IKr; the trig-
ering event is usually by a sudden loud noise such as an alarm
lock. In contrast, LQT3 is caused by the disruption of fast
nactivation of the cardiac sodium-channel SCN5A, resulting
n persistence of the inward sodium current during the plateau
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thep
merican College of Cardiology.
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epolarization and QT interval. LQT3 patients usually have
ymptoms at rest or during sleep and respond poorly to
eta-blockade therapy, but respond very well to mexiletine, a
odium-channel blocker. Furthermore, LQT3 has the highest
revalence of sudden cardiac death. Clinical data derived from
enotyped LQTS patients clearly underscore the differences in
isks and responses to treatment among the variants of LQTS
atients. The advances of our understanding of the electro-
hysiological consequences of these gene mutations make the
henotype–genotype correlation of LQTS patients possible
nd enable physicians to tailor their care of the patients in a
ore logical and less empirical manner.
One of the vital elements of the said advances in LQTS
s the well-known international registry that was created
any years ago. The International LQTS Registry cata-
ogues both talented researchers and LQTS patients from
oth sides of the Atlantic, expediting an otherwise arduous
esearch process, especially if done by a single center.
ubsequently, physicians and scientists from other offspring
QTS registries, created by several renowned institutions,
oined those from the original international registry in
orking on this fascinating inherited genetic arrhythmia.
his collaboration establishes a new way of studying
enotype–phenotype correlation and its impact on diagno-
is, treatment, and risk stratification.
Identifying high-risk asymptomatic LQTS patients for
ardiac arrests or syncope remains an important task for the
cientist and the registry alike. One does not have to be
eminded that when young, otherwise healthy LQTS pa-
ients suddenly die, it devastates family, friends, and loved
nes. The key questions are these: What is the risk for my
aughter/son? What can I do to protect my family in the
uture? Some parents would demand an implantable
ardioverter-defibrillator (ICD), even though data show a
amily history of sudden death does not specifically deter-
ine other cardiac events. Consequently, subjecting a young
symptomatic patient to long-term -blockade therapy or
o ICD treatment is not necessarily an easy task. Therefore,
robust risk-stratification paradigm is desirable in selecting
atients for long-term treatment.
s
t
p
s
t
p
i
I
r
L
t
m
t
r
M
t
t
i
(
u
L
m
l
c
2
t
t
e
t
m
h
t
i
c
m
t
K
r
t
a
t
m
w
p
r
s
s
d
o
s
e
N
r
m
a
a
w
e
t
t
d
n
p
a
d
I
i
t
s
r
o
a
a
p
c
w
e
p
h
s
w
p
R
a
C
E
R
1
2
3
4
5
6
7
2064 Nademanee JACC Vol. 54, No. 22, 2009
Role of Genotyping in Risk Stratification in Type 2 LQTS November 24, 2009:2063–4Thus far, corrected QT (QTc) duration (500 ms) and
ymptoms of syncope or aborted sudden cardiac death are
he best predictors for future events. In asymptomatic
atients, QTc duration is the only useful variable for risk
tratification (4). However, recent data suggest that muta-
ions in the transmembrane portion of the ion channel
rotein and the degree of ion channel dysfunction are
mportant independent risk factors for LQT1 patients (5).
n the same vein, preliminary data from the international
egistry suggest an increased risk of arrhythmic events for
QT2 patients if they have a mutation in the pore region of
he hERG gene when compared with those who have
utations in the nonpore region (6). The investigators from
he international registry then collaborated with the other
egistries—Japan, the Netherlands (Amsterdam), and the
ayo Clinic—to further explore the influence of the loca-
ion, coding type, and topology of the channel mutation on
he clinical manifestation and outcomes of LQT2 patients
n their registries. Their findings, reported by Shimizu et al.
7) in this issue of the Journal, have brought a new level of
nderstanding to the genotype-phenotype relationship in
QT2 patients.
Shimizu et al. (7) found that LQT2 patients who have
issense mutations either at the transmembrane pore (S5-
oop-S6) or at the N-terminus region of the hERG gene,
arry a higher risk of syncope or cardiac arrest (hazard ratio:
.87 and 1.86, respectively), whereas those with the same
ype of mutation, but at the transmembrane nonpore loca-
ion, have a lower risk. When the investigators further
xplored mutation-location interaction for risk stratification,
hey ascertained that LQT2 patients with nonmissense
utation in the C-terminal region were at significantly
igher risk than were patients with the missense mutation at
he same region, a fascinating discovery. Mutations located
n alpha-helical domains are associated with a higher risk of
ardiac events than mutations located in beta-sheet do-
ains. In short, Shimizu et al. (7) are the first to document
hat the type, location, and topology of mutations of the
CNH2 plays an important role in the magnitude of
epolarization abnormality, leading to occurrences of life-
hreatening cardiac arrhythmias.
The question then arises: How does this new observation
ffect our approach in managing asymptomatic LQT2 pa-
ients? For example, if there is a patient who has QTc 500
s but has nonmissense mutation at the N-terminal, then, is
ithholding treatment the correct path? But what if an LQT2
atient has a missense mutation at the transmembrane pore
egion but the QTc is 500 ms (albeit this is not a likely
cenario)? Should one recommend a beta-blocker and a potas-
ium supplement? The study by Shimizu et al. (7) is not really
esigned to answer this question, for it is a retrospective
bservational study to determine genotype-phenotype relation-
hips. The report does not have protocols for determining the
ffects of any therapeutic modalities on the clinical outcomes.
evertheless, beta-blocker treatment in this study reduced the
isk of first cardiac events by 63%; unfortunately, the drug was
K
gostly effective in preventing syncope but not lethal ventricular
rrhythmias. It is a quandary, unless one is willing to implant
n ICD in all of these patients.
Cardioverter-defibrillator implantation in young, other-
ise healthy persons has vices and virtues. While undoubt-
dly an ICD is effective in converting ventricular fibrillation
o sinus rhythm and may save lives, an ICD does not reduce
he risk of recurrences in ventricular arrhythmias and may
eliver unpleasantly frequent shocks to patients, causing a
egative impact. A combination of beta-blocker therapy and
otassium supplements as well as an ICD could be a rational
pproach to preventing lethal arrhythmias, and perhaps the
rug would minimize ICD discharges. However, long-term
CD treatment of the young is known to be associated with
nappropriate shocks or device malfunctions (i.e., lead frac-
ures, insulation breaks, infection). Evidence in the current
tudy reveals significant differences in ICD use among the 4
egistries in this study.
Shimizu et al. (7) enrich our knowledge and understanding
f the genotype–phenotype relationship. This enhances our
bility to identify high-risk LQT2 patients, but leaves us with
therapeutic dilemma of treatment for the patient. It is
ossible that a prospective multicenter study involving the
onsortium of these LQTS registries is required to determine
hether beta-blockade therapy and potassium supplements are
ffective in reducing sudden death in this high-risk LQT2
opulation or whether an ICD is required. Based on what we
ave witnessed with the kind of work done by collaborators
uch as Shimizu et al. (7), I am optimistic that we are on our
ay to finding the optimal solution for our high-risk LQTS
atients in the near future.
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